Cytotoxicity of lymphokine-activated killer cells against human neuroblastoma cells: Modulation by neuroblast differentiation

D. S. Duan, Diana L Farmer, A. A. Rayner, W. Sadee

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The cytolytic activity of lymphokine-activated killer (LAK) cells against human neuroblastoma (NB) cells was investigated using the continuous NB cell lines, IMR-32, Kelly, and two subclones of SK-N-SH, SH-SY5Y (neuroblastic phenotype), and SH-EP (non-neuronal phenotype). NB cells were found to be sensitive targets of LAK. Of the SK-N-SH subclones, the neuroblasts, SH-SY5Y, were more susceptible to LAK killing than were the non-neuronal cells, SH-EP. Pre-treatment of the targets SH-SY5Y and SH-EP with the differentiating agents, retinoic acid (RA, 10 μM), herbimycin A (236 nM), or nerve growth factor (10 ng/ml), did not substantially alter LAK killing. Furthermore, these differentiating agents did not measurably affect LAK activity during the cytolysis assay or with 1-h preincubation of the LAK effectors. However, co-incubation of the LAK cultures over the 3-day activation period with RA (1 μM) or PGE2 (1 μM) inhibited cytolysis by 80%, suggesting that these agents interfere with an early activation step to LAK. These results support the potential use of LAK treatment for neuroblastoma, in combination with differentiation agents that do not affect neuroblastoma sensitivities toward LAK cells. However, some differentiation agents, (e.g. RA) and endogenous prostaglandins (e.g., PGE2) may interfere with LAK activation.

Original languageEnglish (US)
Pages (from-to)339-344
Number of pages6
JournalMedical and Pediatric Oncology
Volume18
Issue number4
DOIs
StatePublished - 1990

Fingerprint

Lymphokine-Activated Killer Cells
Lymphokines
Neuroblastoma
Phenotype
Nerve Growth Factor
Tretinoin
Dinoprostone
Prostaglandins
Cell Line

Keywords

  • LAK
  • neuroblast differentiation
  • neuroblastoma
  • neurosecretions
  • prostaglandins

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Cite this

Cytotoxicity of lymphokine-activated killer cells against human neuroblastoma cells : Modulation by neuroblast differentiation. / Duan, D. S.; Farmer, Diana L; Rayner, A. A.; Sadee, W.

In: Medical and Pediatric Oncology, Vol. 18, No. 4, 1990, p. 339-344.

Research output: Contribution to journalArticle

@article{aab153b7facc4057ba665abae06ff38c,
title = "Cytotoxicity of lymphokine-activated killer cells against human neuroblastoma cells: Modulation by neuroblast differentiation",
abstract = "The cytolytic activity of lymphokine-activated killer (LAK) cells against human neuroblastoma (NB) cells was investigated using the continuous NB cell lines, IMR-32, Kelly, and two subclones of SK-N-SH, SH-SY5Y (neuroblastic phenotype), and SH-EP (non-neuronal phenotype). NB cells were found to be sensitive targets of LAK. Of the SK-N-SH subclones, the neuroblasts, SH-SY5Y, were more susceptible to LAK killing than were the non-neuronal cells, SH-EP. Pre-treatment of the targets SH-SY5Y and SH-EP with the differentiating agents, retinoic acid (RA, 10 μM), herbimycin A (236 nM), or nerve growth factor (10 ng/ml), did not substantially alter LAK killing. Furthermore, these differentiating agents did not measurably affect LAK activity during the cytolysis assay or with 1-h preincubation of the LAK effectors. However, co-incubation of the LAK cultures over the 3-day activation period with RA (1 μM) or PGE2 (1 μM) inhibited cytolysis by 80{\%}, suggesting that these agents interfere with an early activation step to LAK. These results support the potential use of LAK treatment for neuroblastoma, in combination with differentiation agents that do not affect neuroblastoma sensitivities toward LAK cells. However, some differentiation agents, (e.g. RA) and endogenous prostaglandins (e.g., PGE2) may interfere with LAK activation.",
keywords = "LAK, neuroblast differentiation, neuroblastoma, neurosecretions, prostaglandins",
author = "Duan, {D. S.} and Farmer, {Diana L} and Rayner, {A. A.} and W. Sadee",
year = "1990",
doi = "10.1002/mpo.2950180418",
language = "English (US)",
volume = "18",
pages = "339--344",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Cytotoxicity of lymphokine-activated killer cells against human neuroblastoma cells

T2 - Modulation by neuroblast differentiation

AU - Duan, D. S.

AU - Farmer, Diana L

AU - Rayner, A. A.

AU - Sadee, W.

PY - 1990

Y1 - 1990

N2 - The cytolytic activity of lymphokine-activated killer (LAK) cells against human neuroblastoma (NB) cells was investigated using the continuous NB cell lines, IMR-32, Kelly, and two subclones of SK-N-SH, SH-SY5Y (neuroblastic phenotype), and SH-EP (non-neuronal phenotype). NB cells were found to be sensitive targets of LAK. Of the SK-N-SH subclones, the neuroblasts, SH-SY5Y, were more susceptible to LAK killing than were the non-neuronal cells, SH-EP. Pre-treatment of the targets SH-SY5Y and SH-EP with the differentiating agents, retinoic acid (RA, 10 μM), herbimycin A (236 nM), or nerve growth factor (10 ng/ml), did not substantially alter LAK killing. Furthermore, these differentiating agents did not measurably affect LAK activity during the cytolysis assay or with 1-h preincubation of the LAK effectors. However, co-incubation of the LAK cultures over the 3-day activation period with RA (1 μM) or PGE2 (1 μM) inhibited cytolysis by 80%, suggesting that these agents interfere with an early activation step to LAK. These results support the potential use of LAK treatment for neuroblastoma, in combination with differentiation agents that do not affect neuroblastoma sensitivities toward LAK cells. However, some differentiation agents, (e.g. RA) and endogenous prostaglandins (e.g., PGE2) may interfere with LAK activation.

AB - The cytolytic activity of lymphokine-activated killer (LAK) cells against human neuroblastoma (NB) cells was investigated using the continuous NB cell lines, IMR-32, Kelly, and two subclones of SK-N-SH, SH-SY5Y (neuroblastic phenotype), and SH-EP (non-neuronal phenotype). NB cells were found to be sensitive targets of LAK. Of the SK-N-SH subclones, the neuroblasts, SH-SY5Y, were more susceptible to LAK killing than were the non-neuronal cells, SH-EP. Pre-treatment of the targets SH-SY5Y and SH-EP with the differentiating agents, retinoic acid (RA, 10 μM), herbimycin A (236 nM), or nerve growth factor (10 ng/ml), did not substantially alter LAK killing. Furthermore, these differentiating agents did not measurably affect LAK activity during the cytolysis assay or with 1-h preincubation of the LAK effectors. However, co-incubation of the LAK cultures over the 3-day activation period with RA (1 μM) or PGE2 (1 μM) inhibited cytolysis by 80%, suggesting that these agents interfere with an early activation step to LAK. These results support the potential use of LAK treatment for neuroblastoma, in combination with differentiation agents that do not affect neuroblastoma sensitivities toward LAK cells. However, some differentiation agents, (e.g. RA) and endogenous prostaglandins (e.g., PGE2) may interfere with LAK activation.

KW - LAK

KW - neuroblast differentiation

KW - neuroblastoma

KW - neurosecretions

KW - prostaglandins

UR - http://www.scopus.com/inward/record.url?scp=0025290161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025290161&partnerID=8YFLogxK

U2 - 10.1002/mpo.2950180418

DO - 10.1002/mpo.2950180418

M3 - Article

C2 - 1972538

AN - SCOPUS:0025290161

VL - 18

SP - 339

EP - 344

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -